31 results about "Neuropsychiatry" patented technology

The invention is directed to a method of preventing or ameliorating a neuropsychiatric or neurodegenerative disease or disorder in a subject. The method includes administering a composition comprising equol in an amount sufficient to prevent or ameliorate the neuropsychiatric or neurodegenerative disease or disorder. The equol may be a racemic mixture of R-equol and S-equol. The equol may be enantiomerically enriched with R-equol or enantiomerically enriched with Sequol.

A computer implemented method, apparatus, and computer program product for generating neuropsychiatric diagnoses. Quantitative information describing diagnostic characteristics associated with a patient is generated based on an analysis of a set of patient scans. The quantitative information comprises a set of indictors associated with regions of interest in the set of scans for the patient. The set of indicators of potential neuropsychiatric conditions is compared with a set of diagnostic signatures. A diagnostic signature comprises a set of indicators of a known neuropsychiatric condition. Matching signatures are identified. A matching signature is a diagnostic signature that corresponds to at least one indicator in the set of indicators to form a set of signatures. A diagnosis associated with each signature in the set of signatures is identified to form a set of potential diagnoses. The set of potential diagnoses is presented with links to relevant portion of the medical literature.

The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps10p-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and / or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and / or nociception in an individual.

Methods and devices to enhance anti-inflammatory effects in the CNS to treat neurological, neurodegenerative, neuropsychiatric disorders, pain and brain injury are described. Anti-inflammatory enhancing agents that target IL-10 production and signal transduction pathways are discussed. Devices described include therapy delivery devices comprising a reservoir capable of housing an anti-inflammatory enhancing agent and a catheter operably coupled to the device and adapted to deliver the agent to a target site within a subject.

A computer implemented method, apparatus, and computer program product for generating neuropsychiatric diagnoses. Quantitative information describing diagnostic characteristics associated with a patient is generated based on an analysis of a set of patient scans. The quantitative information comprises a set of indictors associated with regions of interest in the set of scans for the patient. The set of indicators of potential neuropsychiatric conditions is compared with a set of diagnostic signatures. A diagnostic signature comprises a set of indicators of a known neuropsychiatric condition. Matching signatures are identified. A matching signature is a diagnostic signature that corresponds to at least one indicator in the set of indicators to form a set of signatures. A diagnosis associated with each signature in the set of signatures is identified to form a set of potential diagnoses. The set of potential diagnoses is presented with links to relevant portion of the medical literature.

An assay for a GCH1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the GCH1 gene, alone or in conjunction with a measurement of low or altered biopterin, or altered BH4 system measures, is used to screen for or diagnose subjects at high risk for developing a psychiatric, neuropsychiatric, or neurological disorders. The assay of the GCH1 genotype, with or without biopterin or a BH4 or BH4 system assay, may also be used to determine antipsychotic or mood stabilizer medication, as well as other treatments. For subjects with an impaired BH4 system, treatments to increase or normalize biopterin, BH4, or the BH4 system can also be used, such as BH4 supplementation, lithium treatment, phenylalanine treatment, or other treatments and therapies.

A method of treating a neurologic or neuropsychiatric disorder or disease in a mammal is provided. The method comprises administering a fatty acid amide hydrolase inhibitor in an amount sufficient to inhibit deamidation of a fatty acid amide. A method of identifying a fatty acid amide hydrolase inhibitor useful in the treatment of a neurologic or neuropsychiatric disorder is also provided. A method of identifying a fatty acid amide or fatty acid useful in the treatment of a neurologic or neuropsychiatric disorder is also provided.

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to improve the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as MS, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.

The present invention provides a panel of at least five clinical analyses or tests (using serum samples) to determine the risk of pediatric acute-onset neuropsychiatric syndrome (PANS) and / or pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) in an individual. These include enzyme linked immunosorbent assays (ELISAs) to measure antibody titers against neuronal antigens present in the brain; the neuronal antigens include lysoganglioside, tubulin, dopamine receptor D1, dopamine receptor D2, serotonin receptor 5HT2A, and serotonin receptor 5HT2C. Antibody titers against at least four of these neuronal antigens are required in the present methods; preferably antibody tiers against all of these neuronal antigens are measured. A final assay is used to quantify calcium / calmodulin-dependent protein kinase activity using a neuronal cell line. The results of these analyses or tests are then combined using an algorithm to determine whether a PANS or PANDAS diagnosis is appropriate for the individual. Depending on the diagnosis, an appropriate treatment can be determined.

This invention provides novel aryl piperazine derivatives represented by Formula (I) having medical utility, in particular as modulators of dopamine and serotonin receptors, preferably the D3, 5HT1A and 5-HT2A receptor subtypes, and in particular useful for the treatment of neuropsychiatric disorders, incl. schizophrenia.

The invention relates to the treatment of disorders associated with elevated myo-inositol levels in brain, in particular behavioural and neuropsychiatry disorders such as dementia, mild Alzheimer's disease, mild cognitive impairment or bipolar disorder by administering an effective amount of scyllo-inositol to a subject.

A transgenic animal other than human in which neuropsychiatric disorder condition is developed by the deletion of an HB-EGF gene is obtained. The present invention relates to a transgenic animal other than human in which an HB-EGF gene is deficient and neuropsychiatric disorder condition is developed, and a production method thereof, and a method for screening a therapeutic agent for neuropsychiatric disorder. As a transgenic animal in accordance with the present invention, a transgenic animal in which an HB-EGF gene is specifically deficient in the spiny neurons (striatum, and hippocampus) can be obtained by crossbreeding a transgenic animal that contains a genotype of Gng7(+ / cre), and a transgenic animal that contains a genotype of Hb-egf(flox / flox).

The present invention relates to chemistry and pharmacy and, in particular, to the production of novel molecular entities, tricyclic and tetracyclic derivatives of benzodiazepine, pyridodiazepine and pyrimidodiazepine type fused with 1,4-dihydropyridine derivatives, having an effect on the central-nervous and vascular systems. Derivatives containing a dihydropyridine ring are used, by means of reactions with compounds of the ortho-phenylenediamine, ortho-diaminopyridine and ortho-diaminopyrimidine type, and also subsequent conversions to some thereof, to obtain tricyclic and tetracyclic derivatives of general formula I-XII that contain a diazepine or diazepinone nucleus fused to a 1,4-dihydropyridine nucleus, in which the A ring is a substituted or unsubstituted benzene, pyridine or pyrimidine ring. These molecular entities exhibit GABAergica and modulating action in the case of calcium channels which can be used in the treatment of cardiovascular, cerebrovascular, neurodegenerative, neuropsychiatric and neurological disorders.

The present invention is based on the discovery and cloning of the human small conductance calcium activated potassium channel type 3 (hKCa3 / KCNN3) gene, which is expressed in neuronal cells, skeletal muscle, heart, and lymphocytes. Alterations in the hKCa3 / KCNN3 gene or its protein product may enhance susceptibility to schizophrenia and / or bipolar disorder. hKCa3 / KCNN3 may be involved in neuropsychiatric, neurological, neuromuscular, and immunological disorders. Substantially purified hKCa3 / KCNN3 polypeptides and polynucleotides are provided. Antibodies which bind to hKCa3 / KCNN3 polypeptides are also disclosed. A method for identifying a compound which affects hKCa3 / KCNN3 polynucleotide or polypeptide is provided. A method for diagnosis and determining the prognosis and treatment regimen of a subject having or at risk of having a hKCa3 / KCNN3-associated disorder is also provided. A method of treating a subject having or at risk of having an hKCa3 / KCNN3-associated disorder by administering a therapeutically effective amount of a polynucleotide encoding SEQ ID NO:2 is also provided. A formulation for administration of hKCa3 / KCNN3 to a patient of a therapeutically effective amount of hKCa3 / KCNN3 polypeptide is provided. Kits useful for detecting the presence of hKCa3 / KCNN3 polypeptide or polynucleotide in a sample from a subject having a hKCa3 / KCNN3-associated disorder are provided. Transgenic nonhuman animals having a transgene encoding hKCa3 / KCNN3 are also described.

This invention relates to treatment of neuro-psychiatricdisorders. Specifically, the invention relates to the use of small molecule agent specific against erbB4, erbB3 or their combination, or fragments thereof in inhibiting the attachment of erbB4, erbB3 or their combination to NRG1.

An assay for a GCH1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the GCH1 gene, alone or in conjunction with a measurement of low or altered biopterin, or altered BH4 system measures, is used to screen or diagnose subjects at risk for developing a psychiatric, neuropsychiatric, or neurological disorder. The genetic assay, with or without a biopterin or BH4 system assay, may also be used to determine treatment regimens. For subjects with an impaired BH4 system, treatments to increase or normalize biopterin, BH4, or the BH4 system can also be used, such as BH4 supplementation, lithium treatment, phenylalanine treatment, or other treatments and therapies.

A dopamine transport protein mimic inhibitor and its use are disclosed. Specific acts on dopamine transport protein, competitive cocaine is located on combined site of dopamine transport protein and it penetrates blood-brain barrier to distribute in brain slowly. It can be used to treat neuropsychiatry and cocaine habituation and has long acting time.